NCT00523718View on ClinicalTrials.gov

Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Obsessive-compulsive DisorderOcd
Interventions
DRUG

riluzole

50 mg PO bid, 12 weeks

DRUG

placebo

placebo, 1 capsule PO bid, 12 weeks

Trial Locations (1)

06508

Yale OCD Research Clinic, New Haven

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Yale University

OTHER

NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder | Biotech Hunter | Biotech Hunter